Global $6.34 Billion Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023

5/8/2017, 5:39 PM (Source: GlobeNewswire)

Dublin, May 08, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023 (Focus on Biomarker Test Type, Application & Market Trends)" report to their offering.

This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others.

This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report.

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market.

The answers to the following key questions can be found in the report:

- What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases?
- How is the tumor biomarker test market evolving?
- What are the market shares of the leading segments of the tumor biomarker test market in 2015?
- How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023?
- How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023?
- How the industry will evolve during the forecast period between 2017 and 2023?
- What are the key developmental strategies implemented in different applications across all regions?
- How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others?
- Which geographical region will lead the global tumor biomarker test market by the end of the forecast period?
- Who are the key players in the tumor biomarker test market?
- What are different application in this market and how are they categorized?
- What are the market trends and key developments in different geographical regions?
- What are all market available cancer biomarker test?
- What is the current market size and future projection for emerging cancer technologies in the major countries?
- What are the key sources of information about emerging cancer technologies?
- What is the incidence rate of major cancer type?

Key Topics Covered:

Executive Summary

1 The Research Scope and Methodology

2 Introduction to Global Emerging Cancer Diagnostics Market
2.1 Overview
2.2 Analysis of Lifestyle Factors
2.2.1 Obesity/Weight
2.2.2 Physical Activity
2.2.3 Food Habits
2.2.4 Alcohol & Cancer Countries with Highest Consumption of Alcoholic Drinks
2.2.5 Salt Consumption
2.2.6 Breastfeeding
2.3 High and Low Developed Countries
2.3.1 Men
2.3.2 Women
2.4 Data for Cancer Frequency by Country
2.4.1 Men
2.4.2 Women
2.5 Worldwide Cancer Data
2.5.1 Men
2.5.2 Women

3 Market Dynamics
3.1 Market Drivers
3.1.1 Increase in Prevalence Rate of Cancer
3.1.2 Increase in Sedentary Lifestyles
3.1.3 Robust Technological Advancement
3.1.4 Environmental Hazards Five Primary Categories of Carcinogens are: -
3.1.5 Government Initiatives and Investment
3.2 Market Challenges
3.2.1 High Capital Investment
3.2.2 Dearth of Skilled Professionals
3.2.3 Lack of Awareness
3.3 Market Opportunities
3.3.1 Nanotechnology Applications in Cancer
3.3.2 3D Printing in Cancer Diagnostics
3.3.3 Robotics in Cancer Diagnostics and Treatment
3.3.4 Fluid Biopsy
3.3.5 Real Time Cancer Diagnostic iKnife

4 Competitive Insights
4.1 Key Market Developments & Strategies
4.1.1 Product Launch and Development
4.1.2 Collaborations, Joint Ventures & Partnerships
4.1.3 Business Expansion and Contracts
4.1.4 Patents, Approvals and Certifications
4.1.5 Mergers and Acquisitions
4.1.6 Other Strategies
4.2 Industry Attractiveness
4.3 Global Market Share Analysis
4.3.1 Market Share Analysis

5 Industry Analysis
5.1 Patent Analysis
5.2 Consortiums, Associations and Regulatory Bodies

6 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast
6.1 Assumptions & Limitations for Analysis and Forecast
6.2 Market Overview
6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test
6.3.1 Prostate Specific Antigen Tests
6.3.2 CTC Tests
6.3.3 Alpha-Fetoprotein (AFP) Tests
6.3.4 CA Test CA 19-9 Tests CA 125 Tests
6.3.5 HER2 Tests
6.3.6 BRCA Test
6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests
6.3.8 EGFR Mutation Tests
6.3.9 KRAS Test
6.3.10 Others National Rental Affordability Scheme (NRAS) Testing RET Gene Testing ROS Testing PIK3CA Tests
6.4 Global Emerging Cancer Diagnostics Market by Application
6.4.1 Lung Cancer
6.4.2 Breast Cancer
6.4.3 Colorectal
6.4.4 Prostate Cancer
6.4.5 Blood Cancer Leukaemia Lymphoma Myeloma
6.4.6 Others
6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography

7 Company Profiles

- Abbott Laboratories, Inc
- LabCorp Of America Holdings
- Luminex Corporation
- Myriad Genetics Inc
- NanoString Technologies Inc
- Neo Genomics Inc
- Quest Diagnostics Incorporated
- Qiagen, Inc
- Roche Holding AG-BR
- Siemens Healthineers
- Thermo Fisher Scientific
- Agilent Technologies
- Biotheranostics, Inc
- Almac group
- GeneNews Limited (formerly ChondroGene Limited)
- Rosetta Genomics
- Epigenomics
- Exact Sciences Corporation
- Ignyta,Inc
- Interpace Diagnostics
- Leica Biosystems
- BioTime, Inc
- Pathway Genomics
- Sysmex Corporation
- AstraZeneca
- Becton Dickinson & Co
- Biocept Inc
- Cancer Genetics Inc
- Danaher Corporation
- Foundation Medicine Inc
- Illumina Inc

For more information about this report visit

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Biomarkers 

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.